Skip to content

Goodwill at other companies

Pfizer logo
PfizerPFE
$71.41B+4.3%
AbbVie logo
AbbVieABBV
$35.57B+0.8%
Incyte logo
IncyteINCY
$133M-14.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$910K0.0%
CG Oncology logo
CG OncologyCGON
$10.3M
Gilead Sciences logo
Gilead SciencesGILD
$8.31B0.0%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.8B+674%
Enterprise value$1.7B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s goodwill?
SELLAS Life Sciences Group, Inc. (SLS) reported goodwill of $1.91M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s goodwill changed year-over-year?
SELLAS Life Sciences Group, Inc.'s goodwill decreased by 0.0% year-over-year, from $1.91M to $1.91M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s goodwill?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $1.91M to $1.91M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.